iTeos Therapeutics
ITOS
Market cap $343M

9.40 USD

-0.21

2.19%

Updated Oct 18, 3:32 PM EDT

1 day

-2.19%

5 days

-4.86%

1 month

-18.90%

3 months

-42.33%

6 months

-9.00%

Year to date

-18.90%

1 year

5.74%

5 years

-50.66%

About: ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Employees: 157

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

16% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 43

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

9% more capital invested

Capital invested by funds: $494M [Q1] → $536M (+$42.5M) [Q2]

2% more funds holding

Funds holding: 133 [Q1] → 135 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

0.98% less ownership

Funds ownership: 101.03% [Q1] → 100.05% (-0.98%) [Q2]

57% less call options, than puts

Call options by funds: $9.69M | Put options by funds: $22.5M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

155%

upside

Avg. target

$34

258%

upside

High target

$46

389%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth 27% 1-year accuracy 24 / 90 met price target	389%upside $46	Buy Reiterated	16 Sept 2024
Wells Fargo Eva Fortea Verdejo 33% 1-year accuracy 1 / 3 met price target	230%upside $31	Overweight Initiated	13 Aug 2024
JP Morgan Brian Cheng 33% 1-year accuracy 4 / 12 met price target	155%upside $24	Overweight Maintained	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Investors Business Daily

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval.

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos to Participate in Upcoming Investor Conferences

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:

iTeos to Participate in Upcoming Investor Conferences

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain.

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

Zacks Investment Research

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago.

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies.

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts. Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations.

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the dosing of the first patient in GALAXIES Lung-301, a global, randomized, double-blind Phase 3 registrational clinical trial of belrestotug + dostarlimab versus placebo + pembrolizumab in patients with first-line advanced, unresectable, or metastatic PD-L1 high NSCLC. This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

See News Rankings

Charts implemented using Lightweight Charts™